On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.

GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday October 27, 2009, are:

**************************************************************

GSK, GlaxoSmithKline plc

GSK, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter medicines, and health related consumer products. GSK operates in two segments, Pharmaceutical and Consumer Healthcare.

** The Food and Drug Administration Monday approved Arzerra, a leukemia treatment that will be marketed by GSK for patients who have failed to respond to other therapies.

More about GSK at www.gsk.com

**************************************************************

EVRN, Everock Inc., EVRN.PK

EVRN produces a line of all-natural gourmet vegetable dips and sandwich spreads marketed under the Nature’s Peak brand.

Both

Genzyme Corp. (GENZ) said it acquired the worldwide rights of marketing leukemia treatment Campath and two other hematological-cancer drugs from its German partner Bayer for up to $650 million in royalties.

As part of the agreement, Genzyme will be responsible for developing Campath to treat multiple sclerosis (MS). However, Bayer will retain an option to co-promote the drug if it gets approval for MS and the right to commercialize Campath for use in organ transplantation.

After selling the rights of Campath, and blood cancer drugs Flurdara and Leukine to Genzyme, Bayer said it will focus on kidney and liver cancer drug Nexavar.

A Bayer spokesperson said the deal "significantly improves the profitability for two of our key franchises - oncology and MS". The company has generated about 220 million euros ($293.2 million) annually from the three drugs.

On the other hand, the deal will

EpiCept Corp. (Nasdaq: EPCT) focuses on advances in the treatment of cancer and pain. The company’s proprietary product, Ceplene, is designed to protect lymphocytes to sustain remission and prevent relapses in adult patients with acute myeloid leukemia (AML) in first remission.

The company today announced the European Commission has granted the company full marketing authorization in 27 member states in the European Union, as well as Iceland, Leichtenstein and Norway. This is especially good news for the company, according to geographical statistics. Approximately 40,000 patients in the EU suffer from AML; about 16,000 new cases are diagnosed each year.

“Today marks a significant and welcome milestone for patients suffering from AML,” Jack Talley, president and CEO of EpiCept stated in the press release. “Ceplene is now the first approved therapy demonstrated to produce a clear benefit in prolonging leukemia-free survival and preventing relapse among AML patients. We are proud that